Inverse regulation of the nuclear factor-κB binding to the p53 and interleukin-8 κB response elements in lesional psoriatic skin

Journal of Investigative Dermatology

Volumn 124, Issue 6, 2005, Pages 1284-1292

  Johansen, Claus ^a,c   Flindt, Esben ^b   Kragballe, Knud ^a   Henningsen, Jeanette ^b   Westergaard, Majken ^b   Kristiansen, Karsten ^b   Iversen, Lars ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

IL 8; NF B; p53 Psoriasis

Indexed keywords

CALCIPOTRIOL; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P50; PROTEIN P53; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BINDING SITE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DNA RESPONSIVE ELEMENT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; NORMAL HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOPICAL TREATMENT;

EID: 20544461306     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23749.x     Document Type: Article

References (40)

1. Asahara H, Asanuma M, Ogawa N, et al: High DNA-binding activity of transcription factor NF-kappa B in synovial membranes of patients with rheumatoid arthritis. Biochem Mol Biol Int 37:827-832, 1995
2. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141-179, 1994
3. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 14:649-683, 1996
4. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
5. Chamian F, Krueger JG: Psoriasis vulgaris: An interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol 16:331-337, 2004
6. Ellis RD, Goodlad JR, Limb GA, et al: Activation of nuclear factor kappa B in Crohn's disease. Inflamm Res 47:440-445, 1998
7. Ellis RD, Limb GA, Thompson RP, et al: NF kappa B in Crohn's disease. Biochem Soc Trans 25:1785, 1997
8. Gearing AJ, Fincham NJ, Bird CR, et al: Cytokines in skin lesions of psoriasis. Cytokine 2:68-75, 1990
9. Ghosh S, Karin M: Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl.):S81-S96, 2002
10. Hammarstrom S, Hamberg M, Samuelsson B, et al: Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc Natl Acad Sci USA 72:5130-5134, 1975
11. Harant H, Wolff B, Lindley IJ: 1Alpha, 25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett 436: 329-334, 1998
12. Jiang WY, Chattedee AD, Raychaudhuri SP, et al: Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 40:699-703, 2001
13. Johansen C, Iversen L, Ryborg A, et al: 1alpha,25-dihydroxyvitamin D3 induced differentiation of cultured human keratinocytes is accompanied by a PKC-independent regulation of AP-1 DNA binding activity. J Invest Dermatol 114:1174-1179, 2000
14. Johansen C, Kragballe K, Rasmussen M, et al: The AP-1 DNA binding activity is decreased in lesional psoriatic skin compared to non-lesional psoriatic skin. Br J Dermatol 151:600-607, 2004a
15. Johansen C, Kragballe K, Westergaard M, et al: The MAP-kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 152:37-42, 2004b
16. Kang S, Yi S, Griffiths, et al: Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 138:77-83, 1998
17. Karin M, Ben Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663, 2000
18. Kim J, Sanders SP, Siekierski ES, et al: Role of NF-kappa B in cytokine production induced from human airway epithelial cells by rhinovirus infection. J Immunol 165:3384-3392, 2000
19. Kragballe K: Vitamin D analogues in the treatment of psoriasis. J Cell Biochem 49:46-52, 1992
20. Kragballe K, Desjarlais L, Marcelo CL: Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol 112:263-270, 1985
21. Kunsch C, Lang RK, Rosen CA, et al: Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J Immunol 153: 153-164, 1994
22. Kunsch C, Rosen CA: NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 13:6137-6146, 1993
23. Lamba S, Lebwohl M: Combination therapy with vitamin D analogues. Br J Dermatol 144 (Suppl. 58):27-32, 2001
24. Larsen CG, Kristensen M, Paludan K, et al: 1,25 (OH)2-D3 is a potent regulator of interleukin-1 induced interleukin-8 expression and production. Biochem Biophys Res Commun 176:1020-1026, 1991
25. Lawrence T, Gilroy DW, Colville-Nash PR, et al: Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7:1291-1297, 2001
26. Liou HC, Baltimore D: Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol 5:477-487, 1993
27. Makarov SS: NF-kappa B in rheumatoid arthritis: A pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 3:200-206, 2001
28. Michel G, Auer H, Kemeny L, et al: Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). Biochem Pharmacol 51: 1315-1320, 1996
29. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866, 1999
30. Pel XH, Nakanishi Y, Takayama K, et al: Benzo[a]pyrene activates the human: p53 gene through induction of nuclear factor kappaB activity. J Biol Chem 274:35240-35246, 1999
31. Riis JL, Johansen C, Cesser B, et al: 1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch Dermatol Res 296:195-202, 2004
32. Saccani S, Pantano S, Natoli G: p38-dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3:69-75, 2002
33. Schottelius AJ, Mayo MW, Sartor RB, et al: Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868-31874, 1999
34. Smith EL, Walworth NC, Holick MF: Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86:709-714, 1986
35. Stern RS: Psoriasis. Lancet 350:349-353, 1997
36. Tak PP, Firestein GS: NF-kappaB: A key role in inflammatory diseases. J Clin Invest 107:7-11, 2001
37. Takao J, Yudate T, Das A, et al: Expression of NF-kappaB in epidermis and the relationship between NF-kappaB activation and inhibition of keratinocyte growth. Br J Dermatol 148:680-688, 2003
38. Terui T, Ozawa M, Tagami H: Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: A neutrophil-associated inflammation-boosting loop. Exp Dermatol 9:1-10, 2000
39. Westergaard M, Henningsen J, Johansen C, et al: Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 121:1104-1117, 2003
40. Yu XP, Bellido T, Manolagas SC: Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 92:10990-10994, 1995